# Mechanistically-Specific Hypotheses: B Cell Tolerance to AQP4
---
## Hypothesis 1: AQP4-Specific B Cell Receptor Editing Mediates Central Tolerance Through RAG-Mediated Secondary V(D)J Recombensation
**Mechanism:** AQP4-reactive B cells in the bone marrow undergo *de novo* V(D)J recombination via reactivation of RAG1/2 expression, replacing self-reactive BCRs with non-autoreactive specificities. This process requires Bach2-mediated transcriptional repression of BCR signaling pathways that would otherwise drive apoptosis rather than receptor editing. Failure of this mechanism permits AQP4-specific B cells to exit into the periphery.
**Key Evidence:** Receptor editing occurs in ~25% of developing B cells with autoreactive specificities (PMID: 11276295); Bach2 is critical for maintaining B cell tolerance by promoting receptor editing over deletion (PMID: 23258293).
**Testable Prediction:** Conditional deletion of RAG1 in CD19-Cre×RAG1-flox mice crossed to AQP4-humanized mice will result in spontaneous anti-AQP4 antibody production and NMO-like pathology by 12 weeks, whereas control mice remain seronegative.
**Target Gene/Protein:** RAG1/RAG2 recombinase complex
---
## Hypothesis 2: Metabolic Anergy in AQP4-Specific B Cells Involves mTORC1 Inhibition and Impaired Glycolytic Flux
**Mechanism:** AQP4-specific B cells adopt a metabolically quiescent state characterized by reduced mTORC1 signaling, decreased Glut1 (SLC2A1) expression, and reliance on oxidative phosphorylation over glycolysis. This metabolic checkpoint prevents the bioenergetic capacity required for antibody production and antigen presentation. Restoration of mTORC1 activity via TSC1 deletion or leucine supplementation breaks this anergic state.
**Key Evidence:** Anergic B cells exhibit reduced mTORC1 activity and impaired metabolic reprogramming upon stimulation (PMID: 27345515); glucose uptake defects underlie B cell tolerance in the AMY1 model (PMID: 24217519).
**Testable Prediction:** B cells from AQP4-tolerant mice treated with leucine (mTORC1 activator) in drinking water will upregulate Glut1 expression and respond to AQP4 immunization with high-titer antibody production, demonstrating that metabolic constraints maintain tolerance.
**Target Gene/Protein:** mTORC1 (MTOR/RPTOR complex)
---
## Hypothesis 3: AQP4-Specific B Cells Express Elevated Levels of FcRL5, Which Couples BCR Engagement to Inhibitory ITIM Signaling
**Mechanism:** FcRL5 (Fc receptor-like 5), an ITIM-bearing receptor, is upregulated on AQP4-specific B cells and recruits SHP-1 (PTPN6) upon BCR crosslinking. This creates a dominant-negative signaling complex that attenuates SYK, BTK, and PLCγ2 activation. Knockdown of FcRL5 converts AQP4-reactive B cells from tolerance to activation, enabling autoantibody secretion.
**Key Evidence:** FcRL5 is preferentially expressed on anergic human B cells and recruits SHP-1 to inhibit BCR signaling (PMID: 20676090); FcRL family members regulate B cell tolerance checkpoints (PMID: 24743342).
**Testable Prediction:** FcRL5 CRISPR-knockout in human AQP4-specific B cells immortalized with EBV will restore calcium flux and proliferative responses to AQP4 tetramers, whereas wild-type cells remain unresponsive.
**Target Gene/Protein:** FcRL5 (FCRL5)
---
## Hypothesis 4: Gut Microbiota-Derived Clostridial Metabolites Induce AQP4-Specific Tfh Cell Apoptosis via Fas-FasL, Preventing B Cell Help
**Mechanism:** Short-chain fatty acids (propionate, butyrate) and secondary bile acids produced by Clostridia species induce apoptosis in AQP4-specific T follicular helper cells through upregulation of Fas (CD95) and engagement by FasL-expressing tolerogenic dendritic cells. This truncates germinal center